Reference is made to the contemplated consolidation of shares in Lifecare ASA (the “Company”) in a ratio of 13:1, as resolved by the extraordinary general meeting of the Company held on 17 September 2024. Reference is further made to the 54,519,478 warrants (the “Warrants”) issued by the Company pursuant to resolutions made by the extraordinary general meeting of the Company held on 16 May 2024. The Warrants shall, pursuant to their terms, be consolidated in the same ratio as the shares (i.e. 13:1).
In order to deliver shares and warrants to persons who own a number of shares and/or warrants that does not compute with the 13:1 ratio for the consolidations, the Company will re-purchase up to 30.000 shares in the Company and up to 7.500 Warrants in the Company, for delivery to such persons. The purchases will be carried out as ordinary trades in the market.
About Lifecare:
Lifecare is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.
This information is subject to disclosure requirements pursuant to the Norwegian Securities Trading Act section 5-12.